Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1 study of AMG 305 in advanced solid tumors
jRCT2031230712Phase 1Completed
- Sponsor
- Amgen
- Start
- Jun 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of AMG 305 in Nonhematologic neoplasms (2 arms), sponsored by Amgen. Primary endpoints: Percentage of participants who experience dose-limiting toxicities, Percentage of participants who experience treatment-emergent adverse events and 1 more. Started Jun 2023; status: completed.
02
Drugs
AMG 305
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031230712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230712.